Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Windtree Therapeutics (NasdaqCM: WINT) announced that Craig Fraser, CEO, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021, at 9:55 am ET. The live webcast will be accessible via the company's Investor Events page. Windtree focuses on late-stage interventions for acute cardiovascular and pulmonary disorders, with its lead candidate, istaroxime, aimed at treating acute heart failure. They also develop AEROSURF® for respiratory distress in infants and are exploring treatments for COVID-19-related respiratory issues.
- None.
- None.
WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.
The Company’s presentation will take place on Wednesday, September 22, 2021 at 9:55 am ET. A live webcast and replay of the presentation will be available on the Investor Events page (https://ir.windtreetx.com/events) of the company’s website (www.windtreetx.com).
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on developing AEROSURF®, a drug-device combination, to deliver its synthetic KL4 surfactant non-invasively to premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK. Windtree is also evaluating KL4 surfactant for the treatment of acute respiratory distress syndrome in COVID-19 patients. Also in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
For more information, please visit the Company's website at www.windtreetx.com.
Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com
Media contact:
Andrew Mielach
LifeSci Communications
646.876.5868 or amielach@lifescicomms.com
FAQ
What will Windtree Therapeutics present at the Oppenheimer Summit?
When is Windtree Therapeutics' presentation scheduled?
How can I access the Windtree Therapeutics presentation?
What is the focus of Windtree Therapeutics?
What are Windtree's leading products?
